Vera Therapeutics Wins FDA Priority Review with July 7 PDUFA; Q1 Loss $121M
VERA•FDA granted priority review to atacicept’s BLA in adult IgA Nephropathy with a PDUFA date of July 7, 2026, positioning Vera for a potential U.S. launch in mid-2026 pending approval. The company reported a Q1 net loss of $121.0M and held $596.8M in cash and equivalents as of March 31, 2026.
1. FDA Priority Review and Upcoming Approval
FDA granted priority review to the atacicept BLA for IgA Nephropathy, assigning a PDUFA date of July 7, 2026 under the accelerated approval pathway. The company also expects initial PIONEER Phase 2 results in Q2 2026 and pivotal ORIGIN 3 eGFR data in Q1 2027.
2. Preparations for Mid-2026 Commercial Launch
Vera advanced key pre-commercial activities across sales, marketing, market access, compliance and operations to support a U.S. launch in mid-2026, pending regulatory approval. Executive team expansion includes promotions and new appointments in commercial, legal and board roles to bolster launch readiness.
3. Q1 2026 Financial Results
For the quarter ended March 31, 2026, Vera reported a net loss of $121.0 million, or $1.69 per diluted share, compared with a $51.7 million loss in Q1 2025. Operating cash use totaled $106.5 million versus $54.4 million in the year-ago quarter, reflecting increased investment in pre-commercial activities.
4. Cash Position and Runway
As of March 31, 2026, the company held $596.8 million in cash, cash equivalents and marketable securities, plus availability under its debt facility. Management expects these resources to fund operations through potential approval and the planned U.S. launch of atacicept in mid-2026.
